Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report

A 47‐year‐old female with ALK‐rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first‐line crizotinib. Alectinib 300 mg was commenced and the patient achieved clinical and radiographic improvements. After nine months of alectinib 300 mg, she started to expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhaona, Li, Pupu, Yan, Bing, Gao, Qiongqiong, Jiang, Xiangli, Zhan, Zhongli, Yan, Qingna, Lizaso, Analyn, Huang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938764/
https://www.ncbi.nlm.nih.gov/pubmed/31766077
http://dx.doi.org/10.1111/1759-7714.13259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938764/
https://www.ncbi.nlm.nih.gov/pubmed/31766077
http://dx.doi.org/10.1111/1759-7714.13259

Ejemplares similares